

# A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab

NCT06389136

---

Status	RECRUITING
Phase	Phase 3
Sponsor	AbbVie
Enrollment	200 participants

## Key Eligibility Criteria

---

### Inclusion (8)

- Chronic AD with onset of symptoms at least 3 years prior to Baseline and subject meets Hanifin and Rajka criteria.
- Participant meets all the following disease activity criteria at Baseline Visit:
- Eczema Area and Severity Index (EASI) score  $\geq 12$ ;
- validated Investigator's Global Assessment for AD (vIGA-AD) score  $\geq 3$ ;
- Body surface area (BSA) involvement of  $\geq 10\%$  in a majority of subjects ( $\geq 50\%$  of the overall study population)

... and 3 more (see full listing online)

### Exclusion (20)

- Meeting any of the following conditions at Baseline:
- Other active skin diseases or skin infections (bacterial, fungal, or viral) requiring systemic treatment within 4 weeks of the Baseline Visit or would interfere with assessment of AD lesions;
- Two or more past episodes of herpes zoster, or one or more episodes of disseminated herpes zoster;
- One or more past episodes of disseminated herpes simplex (including eczema herpeticum);
- HIV infection defined as confirmed positive anti- HIV Ab test;

... and 15 more (see full listing online)

## Locations (121 total)

---

Cahaba Dermatology & Skin Health Center /ID# 263855, Birmingham, Alabama, United States  
One Of A Kind Clinical Research Center - Scottsdale /ID# 278675, Scottsdale, Arizona, United States  
Clinical Trials Institute - Northwest Arkansas /ID# 267290, Fayetteville, Arkansas, United States  
... and 118 more locations